{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:15:03Z","timestamp":1764494103174},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,9]]},"DOI":"10.7759\/cureus.9629","type":"journal-article","created":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T15:13:09Z","timestamp":1596985989000},"source":"Crossref","is-referenced-by-count":9,"title":["Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge"],"prefix":"10.7759","author":[{"given":"Abdul Moiz","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainub","family":"Ajmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihir","family":"Raval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellis","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0931-4","article-title":"COVID-19 outcomes in patients with hematologic disease","author":"Malard F","year":"2020","unstructured":"Malard F, Genthon A, Brissot E, et al.. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020, 10.1038\/s41409-020-0931-4","journal-title":"Bone Marrow Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He W","year":"2020","unstructured":"He W, Chen L, Chen L, et al.. COVID-19 in persons with haematological cancers. Leukemia. 2020, 34:1637-45. 10.1038\/s41375-020-0836-7","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000508199","article-title":"Treating leukemia in the time of COVID-19","author":"Paul S","year":"2020","unstructured":"Paul S, Rausch CR, Jain N, et al.. Treating leukemia in the time of COVID-19. Acta Haematol. 2020, 10.1159\/000508199","journal-title":"Acta Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang W","year":"2020","unstructured":"Liang W, Guan W, Chen R, et al.. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020, 21:335-7. 10.1016\/S1470-2045(20)30096-6","journal-title":"Lancet Oncol"},{"key":"ref5","unstructured":"AML working party COVID-19 recommendations. (2020). Accessed. June 16, 2020: http:\/\/www.cureleukaemia.co.uk\/page\/news\/523\/aml-working-party-covid-19-recommendations.."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00241","article-title":"Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle strategy","author":"Percival MEM","year":"2020","unstructured":"Percival MEM, Lynch RC, Halpern AB, et al.. Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle strategy. J Oncol Pract. 2020, 10.1200\/OP.20.00241","journal-title":"J Oncol Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0925-7","article-title":"Impact of Covid-19 on the treatment of acute myeloid leukemia","volume":"34","author":"Ferrara F","year":"2020","unstructured":"Ferrara F, Zappasodi P, Roncoroni E, Borlenghi E, Rossi G. Impact of Covid-19 on the treatment of acute myeloid leukemia. Leukemia. 2020, 34:2254-2256. 10.1038\/s41375-020-0925-7","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0961-y","article-title":"Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19","author":"N\u00fa\u00f1ez-Torr\u00f3n C","year":"2020","unstructured":"N\u00fa\u00f1ez-Torr\u00f3n C, Garc\u00eda-Guti\u00e9rrez V, Tenorio-N\u00fa\u00f1ez MC, Moreno-Jim\u00e9nez G, L\u00f3pez-Jim\u00e9nez FJ, Herrera-Puente P. Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19. Bone Marrow Transplant. 2020, 10.1038\/s41409-020-0961-y","journal-title":"Bone Marrow Transplant"},{"key":"ref9","article-title":"Hematology in the time of COVID-19 [Article in French]","volume":"16","author":"Gavillet M","year":"2020","unstructured":"Gavillet M, Rufer N, Grandoni F, et al.. Hematology in the time of COVID-19 [Article in French]. Rev Med Suisse. 2020, 16:823-6.","journal-title":"Rev Med Suisse"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 preliminary report","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of Covid-19 \u2014 preliminary report. N Engl J Med. 2020, 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref11","unstructured":"COVID-19 Treatment Guidelines. potential antiviral drugs under evaluation for the treatment of COVID-19. (2020). Accessed: June 16, 2020: https:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/.."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID- 19: systematic review [Epub ahead of print]","author":"Rajendran K","year":"2020","unstructured":"Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID- 19: systematic review [Epub ahead of print]. J Med Virol. 2020, 10.1002\/jmv.25961","journal-title":"J Med Virol"},{"key":"ref13","unstructured":"COVID-19 Treatment Guidelines. immune-based therapy under evaluation for treatment of COVID-19. (2020). Accessed: May 12, 2020: https:\/\/www.covid19treatmentguidelines.nih.gov\/immune-based-therapy\/.."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy577","article-title":"Bezlotoxumab","volume":"68","author":"Johnson S","year":"2019","unstructured":"Johnson S, Gerding DN. Bezlotoxumab. Clin Infect Dis. 2019, 68:699-704. 10.1093\/cid\/ciy577","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox MH","year":"2017","unstructured":"Wilcox MH, Gerding DN, Poxton IR, et al.. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017, 376:305-17. 10.1056\/NEJMoa1602615","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/37754-concurrent-diagnosis-of-acute-myeloid-leukemia-and-covid-19-a-management-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:18:56Z","timestamp":1707506336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/37754-concurrent-diagnosis-of-acute-myeloid-leukemia-and-covid-19-a-management-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,9]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.9629","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,9]]}}}